# Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab

> **NCT03263039** · PHASE2 · UNKNOWN · sponsor: **Erasmus Medical Center** · enrollment: 80 (estimated)

## Conditions studied

- Transitional Cell Carcinoma of the Bladder
- Biomarkers

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03263039
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-21
- **Primary completion:** 2022-08-19
- **Final completion:** 2023-08-19
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2021-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03263039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03263039, "Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03263039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*